Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04002661 · ClinicalTrials.gov registry record · Phase 2
Hypoactive Sexual Desire Disorder in Males
A Phase 2 study, sponsored by Mohit Khera.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT04002661: Clinical Trial Phase 2 study, sponsored by Mohit Khera.
NCT04002661 is a Phase 2 study that was terminated before completion, run by Mohit Khera. The registered enrollment target is 8 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04002661, a Phase 2 study, was terminated before completion, sponsored by Mohit Khera.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the study drug will increase sexual desire in men with HSDD. Half of the participants will take ADDYI while the other half will receive a placebo (a look-alike pill with no medicine).
Primary Outcome
Range 2-10: Number of Participants with a significant change of at least 2 points higher than at screening.
Interventions
- DRUG Placebo
- DRUG Flibanserin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2020-05-08 |
| Est. Completion | 2026-01-23 |
| Phase | Phase 2 |
Why NCT04002661 stopped before completion
NCT04002661 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04002661 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04002661 about?
NCT04002661 is a clinical study titled "Hypoactive Sexual Desire Disorder in Males". The purpose of this study is to determine if the study drug will increase sexual desire in men with HSDD. Half of the participants will take ADDYI while the other half will receive a placebo (a look-alike pill with no medicine).
What is the current status of trial NCT04002661?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2020-05-08. Estimated completion is 2026-01-23.
What interventions are being tested in trial NCT04002661?
The interventions under investigation include: Placebo (DRUG), Flibanserin (DRUG).
Who is sponsoring clinical trial NCT04002661?
This trial is sponsored by Mohit Khera, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04002661's enrollment target sits among peer trials
8 1990th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI